A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations

NCT02492776 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
14
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Collaborators